Email updates

Keep up to date with the latest news and content from Malaria Journal and BioMed Central.

Open Access Highly Accessed Case report

Artemether–lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania

Anna Färnert12*, Johan Ursing12, Thomas Tolfvenstam12, Josea Rono1, Lillemor Karlsson3, Elda Sparrelid2 and Niklas Lindegårdh45

Author Affiliations

1 Infectious Diseases Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

2 Department of Infectious Diseases, Karolinska University Hospital, SE-171 76 Stockholm, Stockholm, Sweden

3 Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden

4 Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

5 Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

For all author emails, please log on.

Malaria Journal 2012, 11:176  doi:10.1186/1475-2875-11-176

Published: 25 May 2012


Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment.

Malaria; P. falciparum; Artemisinin; Lumefantrine; Sensitivity; non-immune